Anika Therapeutics Hits New 52-Week High at $22.28, Signaling Strong Momentum

Anika Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 22.28 on August 10, 2026. This achievement marks a notable increase from its 52-week low of USD 7.92, reflecting a substantial upward movement in the stock's performance over the past year. Despite this recent high, Anika Therapeutics has experienced a one-year performance decline of 19.56%, contrasting sharply with the S&P 500's gain of 21.34% during the same period. The company's market capitalization stands at USD 191 million, indicating its position within the microcap category. Financial metrics reveal that Anika Therapeutics is currently loss-making, with a negative return on equity of -6.96% and a debt-to-equity ratio of -0.39. The stock does not offer a dividend yield, and its price-to-book ratio is 1.33. This recent price movement highlights the stock's volatility and the dynamic nature of the biotechnology industry.